Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2005; 26(5): 520-526
DOI: 10.1055/s-2005-922035
DOI: 10.1055/s-2005-922035
Secondary Lung Tumors in Hematological Patients
Further Information
Publication History
Publication Date:
02 November 2005 (online)
ABSTRACT
Advances made in the field of chemotherapy and radiotherapy have considerably increased the survival of patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). Unfortunately, these antiblastic therapies have also increased the risk of late complications such as second tumors, especially second lung cancers. Although the role of ionizing radiations in carcinogenesis is now clear, less is known about the damage caused by chemotherapy, immunodeficiency induced by drugs or hematological pathologies, and cigarette smoking. In HD, the relative risk (RR) of second lung cancer increases considerably in relation to the dose of ionizing radiation given to the patient, with an RR of 9.6 when more than 9 Gy are administered. Some studies have reported a significantly higher risk of second lung cancers in smokers compared with nonsmokers (p = .03). The role of chemotherapy in the development of second lung cancers has yet to be determined. Although some authors correlate a greater risk with an increased number of chemotherapy cycles, others maintain that chemotherapy increases the risk of second lung cancer only if associated with cigarette smoking. Even less is known about the correlation between NHL and second lung cancer. Although the RR is higher in long-term NHL survivors than in healthy individuals (RR = 1.36), the heterogeneity of histotype and treatment does not permit us to confirm a correlation with chemotherapy and smoking. Conversely, in CLL, the development of second lung cancer appears to be linked to the immunodeficiency that accompanies this hematological malignancy. This is confirmed by the identical RR (1.66) for CLL patients subjected to chemotherapy and for those who have only follow-up.
KEYWORDS
Secondary lung cancer - Hodgkin's disease - non-Hodgkin's lymphoma - chronic lymphocytic leukemia
REFERENCES
- 1 Heyssel R, Brill A B, Woodbury L A et al.. Leukemia in Hiroshima atomic bomb survivors. Blood. 1960; 15 313-331
- 2 Preston D L, Kusumi S, Tomonaga M et al.. Cancer incidence in atomic bomb survivors, III: Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994; 137(Suppl 2) S68-S97
- 3 Thompson D E, Mabuchi K, Ron E et al.. Cancer incidence in atomic bomb survivors, II: Solid tumors, 1958-1987. Radiat Res. 1994; 137(Suppl 2) S17-S67
- 4 Tokunaga M, Land C E, Tokuoka S et al.. Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res. 1994; 138 209-223
- 5 Boice Jr J D. Cancerogenesis: a synopsis on human experience with external exposure in medicine. Health Phys. 1988; 55 621-630
- 6 Boice Jr J D, Land C E, Preston D L.
Ionizing radiation . In: Schottenfeld D, Fraumeni JF Cancer epidemiology and prevention. New York; Oxford University Press 1996: 139-141MissingFormLabel - 7 Ponnaiya B, Cornforth M N, Ullrich R L. Radiation-induced chromosomal instability in BALB/c and C57BL/6 mice: the difference is as clear as black and white. Radiat Res. 1997; 147 121-125
- 8 National Research Council .Health Risk of Radon and Other Internally Deposited Alpha-Emitters. Washington, DC; National Academy Press 1998
MissingFormLabel
- 9 Moolgavkar S H, Luebeck E G, Krewski D, Zielinski J M. Radon, cigarette smoke, and lung cancer: a re-analysis of the Colorado Plateau uranium miners' data. Epidemiology. 1993; 4 204-217
- 10 Yao S X, Lubin J H, Qiao Y L et al.. Exposure to radon progeny, tobacco use and lung cancer in a case-control study in southern China. Radiat Res. 1994; 138 326-336
- 11 Kaldor J M, Day N E, Clarke E A et al.. Leukemia following Hodgkin's disease. N Engl J Med. 1990; 322 7-13
- 12 van Leeuwen F E, Klokman W J, Hagenbeek A et al.. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994; 12 312-325
- 13 Kaldor J M, Day N E, Pettersson F et al.. Leukaemia following chemotherapy for ovarian cancer. N Engl J Med. 1990; 322 1-6
- 14 Curtis R, Boice Jr J D, Stovall M et al.. Risk of leukaemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992; 326 1745-1751
- 15 Henry-Amar M. Second cancer after treatment for Hodgkin's disease: a report from the International database on Hodgkin's Disease. Ann Oncol. 1992; 3(Suppl 4) S117-S128
- 16 Kaldor J M, Day N E, Bell J et al.. Lung cancer following Hodgkin's disease: a case control study. Int J Cancer. 1992; 52 677-681
- 17 Tucker M A, Murray N, Shaw E G et al.. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997; 89 1782-1788
- 18 van Leeuwen F E, Klokman W J, Veer M B et al.. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000; 18 487-497
- 19 Mauch P M, Kalish L A, Marcus K C et al.. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996; 87 3625-3632
- 20 Breslow N E, Takashima J R, Whitton J A, Moksness J, D'Angio G J, Green D M. Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1995; 13 1851-1859
- 21 Relling M V, Rubnitz J E, Rivera G K et al.. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999; 354 34-39
- 22 Birdwell S H, Hancock S L, Varghese A, Cox R S, Hoppe R T. Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1997; 37 67-73
- 23 Hoppe R T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997; 8(Suppl 1) S115-S118
- 24 Dores G M, Metayer C, Curtis R E et al.. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20 3484-3494
- 25 van Leeuwen F E, Klokman W J, Stovall M et al.. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995; 87 1530-1537
- 26 Travis L B, Gospodarowicz M, Curtis R E et al.. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002; 94 182-192
- 27 Swerdlow A J, Schoemaker M J, Allerton R et al.. Lung cancer after Hodgkin's disease: a nested case-control study of the relation treatment. J Clin Oncol. 2001; 19 1610-1618
- 28 Colvin O M.
Antitumor alkylating agents . In: De Vita VT Jr, Hellman S, Rosenberg SA Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia; Lippincott Williams & Wilkins 2001: 363-376MissingFormLabel - 29 Rudiger H W, Schwartz U, Serrand E et al.. Reduced O6-methylguanine repair in fibroblast cultures from patients with lung cancer. Cancer Res. 1989; 49 5623-5626
- 30 Kaur T B, Travaline J M, Gaughan J P, Richie Jr J P, Stellman S D, Lazarus P. Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000; 9 339-342
- 31 Palmisano W A, Divine K K, Saccomanno G et al.. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60 5954-5958
- 32 Hecht S S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999; 91 1194-1210
- 33 Peterson L A, Liu X K, Hecht S S. Pyridyloxobutyl DNA adducts inhibit the repair of O6-methylguanine. Cancer Res. 1993; 53 2780-2785
- 34 Peters M V, Middlemiss K C. A study of Hodgkin's disease treated by irradiation. Am J Roentgenol Radium Ther Nucl Med. 1958; 79 114-121
- 35 Devita Jr V T, Serpick A A, Carbone P P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970; 73 881-895
- 36 Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer. 1975; 36 252-259
- 37 Diehl V, Mauch P M, Harris N L.
Hodgkin's disease . In: De Vita VT Jr, Helleman S, Rosenberg SA Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia; Lippincott Williams & Wilkins 2001: 2339-2387MissingFormLabel - 38 Ng A K, Mauch P M. Radiation therapy in Hodgkin's lymphoma. Semin Hematol. 1999; 36 290-302
- 39 Kaldor J M, Day N E, Band P et al.. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer. 1987; 39 571-585
- 40 Swerdlow A J, Barber J A, Hudson G V et al.. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000; 18 498-509
- 41 Travis W D, Travis L B, Devesa S S. Lung cancer. Cancer. 1995; 75(Suppl 1) S191-S202
- 42 The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329 987-994
- 43 Coiffier B, Lepage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346 235-242
- 44 Zarrabi M H. Association of non-Hodgkin's lymphoma (NHL) and second neoplasms. Semin Oncol. 1980; 7 340-341
- 45 MacDougall B K, Weinerman B H, Kemel S. Second malignancies in non-Hodgkin's lymphoma. Cancer. 1981; 48 1299-1301
- 46 Travis L B, Curtis R E, Glimelius B et al.. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993; 85 1932-1937
- 47 Andre M, Mounier N, Leleu X et al.. Second cancers and late toxicities after treatment of aggressive non-Hodgkin's lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004; 103 1222-1228
- 48 Travis L B, Curtis R E, Hankey B F, Fraumeni Jr J F. Second cancer in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992; 84 1422-1427
- 49 Hisada M, Biggar J, Green M H, Fraumeni Jr J F, Travis L B. Solid tumors after chronic lymphocytic leukemia. Blood. 2001; 98 1979-1981
- 50 Linet M S, Cartwright R A.
Leukaemia . In: Schottenfeld D, Fraumeni JF Jr Cancer Epidemiology and Prevention. 2nd ed. New York; Oxford University Press 1996: 841-892MissingFormLabel - 51 Robak T, Blonski J Z, Gora-Tybor J et al.. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer. 2004; 40 383-389
- 52 Cheson B D. Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995; 13 2431-2448
- 53 Cheson B D, Vena D A, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999; 17 2454-2460
- 54 Potti A, Ganti A K, Koch M, Mehdi S A, Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. Lung Cancer. 2001; 34 227-232
- 55 Stephens P, Hunter C, Bignell G et al.. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004; 431 525-526
Dino AmadoriM.D.
Division of Oncology and Diagnostics, Ospedale G. B. Morgagni
Via C Forlanini 34, 47100 Forlì, Italy
Email: segronco@ausl.fo.it